{
    "nct_id": "NCT04427566",
    "official_title": "Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise",
    "inclusion_criteria": "* Laboratory Diagnosis of COVID-19 based within 14 days of enrollment.\n* CT or radiographic findings typical of COVID-19 pneumonia within 5 days of enrollment\n* Receiving ICU-based mechanical ventilation\n* Life expectancy ≥ 24 hours, as judged by investigator\n* Hypoxemia defined as a Pa/FIO2 ratio < 300 or SpO2/FiO2 < 315\n* Signed informed consent by patient or his or her legal/authorized representative\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Moribund with survival expected < 24 hours, as judged by investigator and treating team\n* Expected survival < 30 days, as judged by investigator and treating team, due to chronic illness present prior to COVID infection\n* Patient or legal representative not committed to full disease specific therapy, i.e. comfort care (DNRCCA is allowed)\n* Treatment with immune suppressing medications in the last 30 days (steroids for acute respiratory distress syndrome or septic shock allowed)\n* Presumed COVID-associated illness greater than 14-days\n* Inpatient admission greater than 14-days\n* Patient deemed unsafe for travel for radiation therapy\n* Chronic hypoxemia requiring supplemental oxygen at baseline\n* Documented active connective tissue disease (scleroderma) or idiopathic pulmonary fibrosis\n* History of prior radiation therapy resulting in ≥grade 2 radiation pneumonitis within 365 days of enrollment\n* Active or history of prior radiation to the thorax completed within 180 days of enrollment (skin or surface only skin treatments are acceptable)\n* Known active uncontrolled bacterial or fungal infections of the lung.\n* Active cytotoxic chemotherapy\n* Females who are pregnant or have a positive pregnancy test\n* Breast feeding\n* Note: concurrent administration of convalescent immune plasma therapy either on clinical trial or as a standard therapy not an exclusion criterion, but will be noted",
    "miscellaneous_criteria": ""
}